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Abstract
Background/Objectives: Higher fibre intakes are associated with risk reduction for chronic diseases. However,
many people find difficulty in consuming sufficient fibre through their diet. Supplements may be an effective
alternative. We aimed to investigate the effects of PolyGlycopleX® (PGX®), a proprietary polysaccharide complex and
a proprietary Psyllium product (PgxSyl™) (PSY) on diet, body weight and composition in overweight and obese
individuals.
Subjects/Methods: This was a double-blind 52 weeks study with 159 people randomized to 3 groups: control
(rice flour); PGX (PGX) and proprietary psyllium (PSY). Participants did not change any of their usual habits or diet
except they consumed 5 g of supplement taken with a total of 500 ml of water 5–10 min before meals.
Results: Weight was significantly lower in the PGX group compared to control at 3 (−1.6 kg [0.57, 2.67, p = 0.003]),
6 (−2.6 kg [1.01, 4.13, p = 0.001]) and 12 months (−2.6 kg [0.59, 4.64, p = 0.012]) and in the PSY group compared to
control group at 3 (−1.1 kg [0.07, 2.12, p = 0.037]) and 6 months (−2.4 kg [0.95, 3.93, p = 0.002]). This was a
difference of − 2.8% for the PGX group and − 1.5% for the PSY group compared to control after 12 months
supplementation. Body Fat was significantly lower in PGX compared to control at 6 (−1.8 kg [0.63, 2.95, p = 0.003])
and 12 months (−1.9 kg [0.43, 3.36, p = 0.012]) and in PSY compared to control at 6 (−1.9 kg [0.84, 3.04, p = 0.001])
and 12 months (−1.4 kg [0.08, 2.71, p = 0.038]).
Conclusions: PGX was better than PSY at maintaining dietary changes and weight loss over the 12 month
intervention period, with no change to exercise. A simple strategy of PGX supplementation may offer an effective
solution to long-term weight-loss and then management without the need for other nutrient modification.
Trial registration: ANZCTR: ACTRN12611000415909. Registered 20 April 2011
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Background
Dietary fibre recommendations for adults in Australia,
Canada and the USA are 25–30 g/d to be consumed
from fibre-rich foods [1]. However it is estimated that
these countries’ adults consume approximately 15–25 g
of dietary fibre/d [2, 3]. Epidemiological and cohort stud-
ies have consistently revealed that higher fibre intakes are
correlated with lower body weight, body mass index
(BMI), waist circumference [4, 5], improved lipid profiles
[2, 6–14], glycaemia and insulinaemia [15]; indicating the
benefits and risk reduction for metabolic syndrome,
cardiovascular disease and type 2 diabetes.
Although the benefits of fibre are well known, people,
in general, find it difficult to eat the required amounts of
fibre by increasing fruit and vegetable intake [16]. There-
fore, fibre supplements can provide an easy, cost effect-
ive method for increasing fibre intake without the need
for other major nutrient modifications.
PolyGlycopleX® (PGX®)
PolyGlycopleX (PGX) is a novel, highly viscous functional
non-starch polysaccharide complex, with developing
viscosity, manufactured by a proprietary process (Enviro-
Simplex®) from konjac (glucomannan), sodium alginate
and xanthan gum. Adding 2.5–5 g of PGX to a meal is
highly effective in reducing postprandial glycaemia, lower-
ing the glycaemic index of food [17] and modifying satiety
hormones in healthy adults [18].
Psyllium fibre
Psyllium is one of the most widely used fibre supple-
ments in Australia because it is reasonably cheap, is
available in several flavours and sold as powdered drink
mixes, capsules or wafers. Psyllium has advantages over
other types of soluble fibre because it is less readily
fermented and therefore causes less flatulence and ab-
dominal bloating [19]. Psyllium is a soluble fibre and has
been evaluated in various human studies for beneficial
effects on glucose and insulin homeostasis, lipids and
lipoprotein, body weight, body composition and appetite
[20–28]. Therefore PSY was chosen as a positive control
to examine whether PGX would be as good as or better
than PSY. Psyllium intake was reviewed (2012) for its
effect on metabolic syndrome [29]. The authors con-
cluded, “Collectively, research to date does support the
notion that the consumption of psyllium may provide
benefits to many components of the metabolic syndrome.”
Psyllium fibre seems to improve body weight in animals
[30] but human studies remain controversial, with most
showing no improvement on body weight and body com-
position after psyllium consumption [21, 24–26].
PGX is the most viscous soluble fibre, 3–5 times more
viscous than any known individual polysaccharide [31].
Although it is considered natural, it is a blend of 3
different fibres: konjac (glucomannan), sodium alginate
and xanthan gum. Psyllium has a similar physical ap-
pearance as PGX in its powder form but has a lower
viscosity.
Both PGX and psyllium are viscous fibers which ab-
sorb large amounts of water and form gels that increase
feelings of fullness, [32] this may cause people to con-
sume less food. The thickening of gut contents decreases
intestinal passage rates, prolongs nutrient absorption
and hence causes satiety [33], thus PGX with a greater
viscosity has a greater effect on satiety and reduced food
intake [32]. Given the greater viscosity, it was hypothe-
sized that PGX would have better metabolic outcomes
in this clinical trial.
Randomized, blinded, placebo controlled clinical trials
are required to verify whether PGX® can be used for long
term weight loss programs. Therefore the aim of this
study was to investigate the effect of PGX on body
weight and composition when compared to a proprietary
Psyllium (PgxSyl™) product and a placebo. Given the
effect of PGX on postprandial glycemia/insulinemia and
its considerably higher viscosity, we hypothesize that
PGX will demonstrate a greater improvement of body
weight loss and composition than the psyllium product
or placebo in individuals with overweight and obesity.
Methods
Subjects
Individuals with overweight and obesity (BMI 25–
47 kg/m2) were recruited from the community in
Perth, Australia and screened by telephone or online
questionnaire. Exclusion criteria included smoking,
medication and other agents that may influence lipid me-
tabolism, diabetes mellitus, hypo- and hyperthyroidism,
cardiovascular events within the last 6 months, major
systemic diseases, gastrointestinal problems, weight
fluctuations over the past 6 months, and participation in
any other clinical trials within the last 6 months.
Study design
This was a randomized, double-blind, parallel design study
over a 52 weeks period, with recruitment and the inter-
vention conducted from February 2012 to September 2013.
Participants were equally randomized by the trial sponsors
using a Web site [http://www.randomization.com/] to one
of three groups (3 randomly permuted blocks): the control
group who consumed the placebo with their usual diet; the
psyllium group (PSY) who consumed a psyllium supple-
ment with their usual diet and a PGX group (PGX) who
consumed a PGX supplement with their usual
diet. The supplementation (InovoBiologic Inc., Calgary,
Canada) consisted of either 5 g of psyllium or 5 g of PGX.
Placebo consisted of 5 g rice flour, an appropriate placebo
due to its low energy and fibre content but similarity in
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texture and appearance to the psyllium and PGX. All sup-
plements were artificially sweetened (aspartame), naturally
flavoured (citric acid and orange) and coloured (sunset
yellow FCF). Participants were instructed to take supple-
ments mixed with a minimum of 250 mL water followed
by an additional 250 mL water (500 mL total), three times
daily, 5–10 min before meals. Packages were identical and
were only marked by the participant ID (sequentially
numbered), with the group allocation only known to the
trial sponsors to ensure blinding. All identifiable informa-
tion from participants was coded to ensure privacy.
The subjects attended a briefing session on how to
consume the supplement, complete food records and
comply with the study protocol as previously reported
[34]. All participants were asked to maintain their usual
dietary intake and physical activity for the duration of
the study. To monitor compliance, participants com-
pleted a diary to record their supplement consumption
and asked to return the empty and non-empty sachets of
the supplements at visits.
Anthropometry and body composition
Measures of weight, height, waist and hip circumference
were undertaken at baseline, 3, 6 and 12 months. Weight
(HBF-514, Omron, Kyoto, Japan) was recorded in light
clothing without shoes and height was measured using a
stadiometer. Waist circumference was measured in the
standing position at the narrowest area between the lat-
eral lower rib and the iliac crest. Hip measurement was
taken at the largest circumference of the lower abdomen.
Total body fat, lean mass, android fat and gynoid fat
were assessed by whole body dual-energy X-ray ab-
sorptiometry (DXA; Lunar Prodigy, Lunar, Madison
WI, USA) at baseline, 6 and 12 months. Android fat
(fat around the abdomen) and gynoid fat (fat around
the hips) regions were automatically obtained by the
GE Lunar Prodigy software. Body fat distribution var-
ies by gender as women tend to have greater gynoid
fat than men [35].
Diet and physical activity
Participants completed 3-day food and drink diaries at
baseline, 3, 6 and 12 months to monitor for changes in
food intake. Data were analysed with Foodworks 7
Professional (Xyris Software, Australia). Participants also
completed the International Physical Activity Question-
naire (short version) at the same time points to monitor
physical activity levels.
Statistical analysis
A sample size of 24 subjects/group was predicted to
provide sufficient power (80%) to detect a 3% difference
in weight within a group. Calculations were based on a
mean weight of 80 kg and a standard deviation of 5%
within a group on all eligible subjects. We recruited 53
subjects/group to accommodate for 50% dropouts.
Statistical analysis was undertaken using SPSS 22 for
Windows (SPSS Inc., Chicago, IL, USA). Data were
expressed as mean (± SEM) and assessed for normality.
Baseline differences between groups was analysed with
one-way ANOVA. Changes from baseline within a group
were analysed with paired T-test. The data were analysed
using General Linear Models with baseline value covari-
ates. If significant between groups effects were present,
post hoc comparisons between the treatment groups
was made using the Least Significant Difference
(LSD) method. Statistical significance was considered
at p <0.05. There were no significant differences
between genders when sex was used as a factor in
the analysis of variance for each parameter reported,
i.e. diet, physical activity, body weight and body com-
position at each time point.
Patient involvement
No patients were involved in the design, recruitment to
or conduct of the study or in the development of the
research question and outcome measures. Individual
results were sent to participants. The burden of the
intervention on participants was not assessed.
Results
Participants
The 159 participants (19 to 68 y) who met the eligibility
criteria were randomized to one of three groups (Control,
PGX, PSY) by assignment of an ID number from 001 to
159 and the corresponding numbered supplement. Partici-
pant flow through the study can be seen in Fig. 1. 127 par-
ticipants (54 male, 73 female) completed at least 3 months
of the study and were included in the analysis (45 in
Control [24 male], 39 in PGX [15 male] and 43 in PSY
[15 male]).
Baseline characteristics
There were no significant differences at baseline between
groups for major characteristics, energy intake, macro-
nutrients or fibre intake (Table 1).
Diet
The dietary analysis can be seen in Table 2. We observed
significant decreases in energy intake in the PGX group
at 3 months (p = 0.001), 6 months (p = 0.009) and
12 months compared to baseline (p = 0.012). Energy
intake was significantly lower in the PSY group at
3 months (p = 0.000), 6 months (p = 0.000) and
12 months (p = 0.001) compared to baseline. When
examining differences between groups, energy intake
was significantly lower compared to control at
3 months in the PGX® (−16.2%, p = 0.000) and PSY
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(−19.3%, p = 0.000) groups, at 6 months in PGX
(−15.3%, p = 0.002) and PSY (−14.4%, p = 0.002)
groups compared to control and at 12 months in the
PGX group (−11%, p = 0.049) compared to control.
Carbohydrate intake was significantly lower com-
pared to control at 3 months in the PGX (p = 0.001)
and PSY (p = 0.004) groups and at 6 months in PGX
(p = 0.019) and PSY (p = 0.001) groups compared to
control. Fat intake was significantly lower compared
to control at 3 months in the PGX (p = 0.014) and
PSY (p = 0.000) groups and at 6 months in the PGX
group (p = 0.045) compared to control. Protein intake
was significantly lower compared to control at
3 months in the PGX (p = 0.006) and PSY (p = 0.000)
groups and at 6 months in the PGX® group (p =
0.002) compared to control. Compared to baseline,
carbohydrate intake was significantly lower for both
PGX and PSY groups at all time points. Fat and pro-
tein intakes were inconsistent during the 12 month
study period.
Dietary fibre intake from food was significantly lower
compared to control at 6 months in the PGX (p = 0.045)
group. Fibre intake from food was significantly lower in
the PSY group at 6 months (p = 0.005) compared to
baseline. Total fibre intake in the PGX and PSY inter-
vention groups was 15 g/day higher than fibre intake
from food, as participants were consuming three 5 g
fibre supplements each day. This was a significant
increase compared to baseline and compared to the
control group for both PGX and PSY groups.
Physical activity
Physical activity levels did not significantly change from
baseline within any groups and there were no significant
differences between groups at any time point (Table 3).
Body weight
Weight and BMI were significantly lower in the PGX
group at 12 months compared to baseline (p < 0.05),
Fig. 2a shows change in body weight Fig. 2b shows
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Fig. 1 Participant flow diagram
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change in BMI. Weight was significantly lower
compared to control at 3 months in the PGX (−1.7%,
p = 0.007) and PSY (−1.2%, p = 0.037) groups, at
6 months in PGX (−2.7%, p = 0.001) and PSY (−2.6%,
p = 0.002) groups compared to control and at
12 months only in the PGX group (−2.8%, p = 0.012)
compared to control. BMI was significantly lower
compared to control at 3 months in the PGX (p =
0.004) and PSY (p = 0.042) groups, at 6 months in
PGX (p = 0.001) and PSY (p = 0.001) groups compared
to control and at 12 months only in the PGX group
(p = 0.010) compared to control.
Waist circumference was significantly lower (p < 0.01)
in the PGX and PSY groups at 3 months, 6 months and
12 months compared to baseline, Fig. 2c. Waist was
significantly lower compared to control at 3, 6 and
12 months in the PGX and PSY groups (p < 0.01) com-
pared to control.
Hip was significantly lower in the PGX group at 6 and
12 months (p < 0.05) compared to baseline. Hip was sig-
nificantly lower in the PSY group 6 months (p = 0.009)
compared to baseline. Hip was significantly lower com-
pared to control at 6 months in PGX (p = 0.034) and
PSY (p = 0.004) groups compared to control and at
12 months only in the PGX group (p = 0.008) compared
to control, Fig. 2d.
WHR was significantly lower in the PGX group at 3 and
6 months compared to baseline and in the PSY group at 3,
6 and 12 monthsnths compared to baseline (p < 0.05).
WHR was significantly lower in the PSY group compared
to control at 3 and 6 months (p < 0.05), Fig. 2e.
DXA Body fat
The amount of change of body fat was significantly
lower in the PSY and PGX groups at 6 months and in
PGX group at 12 mo (p < 0.05) compared to baseline.
Body fat was significantly lower compared to control at
6 months in the PSY (p = 0.001) and PGX® (p = 0.003)
groups and at 12 months in the PSY (p = 0.038) and
PGX groups (p = 0.012) compared to control, Fig. 3a.
Body fat % was significantly lower in the PGX and PSY
groups at 6 months compared to baseline (p < 0.05).
Body fat % was significantly lower compared to control
at 6 months in the PGX (p = 0.020) and PSY (p = 0.002)
groups and at 12 months in the PGX (p = 0.008) and
PSY groups (p = 0.018) compared to control, Fig. 3b.
Android fat was significantly lower in the PGX and
PSY groups at 6 and 12 months (p < 0.05) compared to
baseline. Android fat was significantly lower compared
to control at 6 months in the PGX (p = 0.004) and
PSY (p = 0.003) groups and at 12 months in the PGX
(p = 0.003) and PSY groups (p = 0.005) compared to
control, Fig. 3c. Gynoid fat was significantly lower in
the PSY group at 6 and 12 months (p < 0.05) compared to
baseline. Gynoid fat was significantly lower compared to
control at 6 months in the PGX® (p = 0.028) and PSY (p =
0.002) groups and at 12 months in the PGX (p = 0.010)
and PSY groups (p = 0.003) compared to control, Fig. 3d.
Lean mass % was significantly higher in the PGX
and PSY groups at 6 months (p < 0.05) compared to
baseline. Lean mass % was significantly higher com-
pared to control at 6 months in the PGX (p = 0.035) and
PSY (p = 0.002) groups and at 12 months in the PGX (p =
0.008) and PSY groups (p = 0.017) compared to control,
Fig. 3e.
Adverse events
Minor adverse events were gastrointestinal related (e.g.
flatulence, diarrhoea) with four participants withdrawing







Gender (M/F) 24/21 15/28 15/24
Age (y) 49.8 ± 1.8 49.9 ± 1.7 47.9 ± 1.9
Height (cm) 171.7 ± 1.5 169.2 ± 1.6 169.8 ± 1.7
Weight (kg) 94.7 ± 2.5 91.2 ± 2.2 96.2 ± 2.9
BMI (kg/m2) 32 ± 0.6 31.7 ± 0.5 33.2 ± 0.7
Waist (cm) 103.1 ± 1.6 101.2 ± 1.5 106 ± 2
Hip (cm) 112.9 ± 1.3 114.6 ± 1.3 115.7 ± 1.5







Fat (kg) 37.3 ± 1.4 38.6 ± 1.2 38.3 ± 1.3
Fat % 40.2 ± 1.2 40.89 ± 1.1 41.1 ± 1.2
Android Fat (kg) 3.8 ± 0.2 3.5 ± 0.2 3.9 ± 0.2
Gynoid Fat (kg) 6.1 ± 0.3 6.3 ± 0.2 6.2 ± 0.3
Lean (kg) 53 ± 1.9 50.4 ± 1.7 52.8 ± 2.2







Energy (kJ/d) 8636.4 ± 294.4 8859.4 ± 318.4 8783.3 ± 261.3
Carbohydrate (g/d) 209.8 ± 8.8 212 ± 8.9 209.8 ± 8.6
Fat (g/day) 80.2 ± 4.2 81.2 ± 4.5 82.8 ± 3.3
Protein (g/d) 101.7 ± 4 104 ± 4.7 101.6 ± 3.9









3058 ± 591 3133 ± 453 2135 ± 432
Values are mean ± SEM. PGX (PolyGlycopleX) MET (Metabolic Equivalent of
Task). aOne participant in the PGX group was unable to have the DXA scan.
bPhysical activity logs missing (n = 10). P values were not significant.
4.184 kJ = 1 kCal
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Table 2 Dietary intake during 12 months of fibre supplementation
Variable 3 months Mean change n P 6 months Mean change n P 12 months Mean change n P
Energy (kJ/d) CTR 9013.1 ± 223.6a 115.5 39 NS 8803.3 ± 282.9a 32 34 NS 8218 ± 295.4a −529.7 31 NS
PSY 7272.3 ± 218b −1617.3 41 0.000 7539.2 ± 278.8b −1229.2 35 0.000 7657.1 ± 277.9ab −1202 35 0.001
PGX 7556.3 ± 243.1b −1090.9 33 0.001 7453.7 ± 323.5b −1080.7 26 0.009 7315.3 ± 342.4b −1226.4 23 0.012
CHO (g/d) CTR 212.6 ± 7.7a −1.6 39 NS 213.4 ± 10a 3.4 34 NS 200.5 ± 8.4 −10.3 31 NS
PSY 181 ± 7.5b −31.8 41 0.002 164.7 ± 9.8b −39.9 35 0.002 183.9 ± 7.9 −26 35 0.015
PGX 175.3 ± 8.4b −31.5 33 0.003 177.2 ± 11.4b −22.1 26 0.032 176.3 ± 9.7 −25.6 23 0.012
Fat (g/d) CTR 83.8 ± 3.2a −0.5 39 NS 82.3 ± 4.3a −0.6 34 NS 73 ± 4 −9.5 31 NS
PSY 66.9 ± 3.1b −15.6 41 0.000 72.9 ± 4.2ab −8.6 35 NS 73 ± 3.8 −9.6 35 NS
PGX 72.2 ± 3.4b −9 33 NS 69.1 ± 4.9b −10.5 26 0.047 66 ± 4.7 −15.2 23 0.020
Protein (g/d) CTR 109.9 ± 3.7a 6.4 39 NS 105.2 ± 4.1a 3.1 34 NS 99.4 ± 4.7 −2.1 31 NS
PSY 85.9 ± 3.6b −17.6 41 0.000 96.7 ± 4ab −6.7 35 NS 88 ± 4.4 −15.3 35 0.003
PGX 94.4 ± 4.1b −6.5 33 NS 85.7 ± 4.7b −15.7 26 0.004 89.2 ± 5.4 −10.2 23 NS
Fibre from diet (g/d) CTR 24.2 ± 1.2 0.8 39 NS 22.1 ± 1a −0.4 34 NS 21.6 ± 1.3 −1 31 NS
PSY 21.4 ± 1.2 −2.3 41 NS 20.1 ± 0.9ab −2.9 35 0.005 21.6 ± 1.3 −2.4 35 NS
PGX 21.6 ± 1.3 −0.6 33 NS 19.1 ± 1.1b −2.2 26 NS 21.1 ± 1.6 −1 23 NS
Total Fibre (g/d) CTR 24.2 ± 1.2a 0.8 39 NS 22.1 ± 1a −0.4 34 NS 21.6 ± 1.3a −1 31 NS
PSY 36.4 ± 1.2b 12.7 41 0.000 35.1 ± 0.9b 12.1 35 0.000 36.6 ± 1.3b 12.6 35 0.000
PGX 36.6 ± 1.3b 14.2 33 0.000 34.1 ± 1.1b 12.5 26 0.000 36.1 ± 1.6b 13.8 23 0.000
Values are mean ± SEM with baseline as a covariate. Mean change from baseline. P values are within group differences compared to baseline. Different letters in superscript represent significant differences between












from the study, two in the PGX group and two in the
control group. The PSY supplement was better tolerated
and participants did not report any adverse effects.
Discussion
This study investigated the effects of daily consumption
of 15 g of PGX or PSY compared to control (rice flour)
for 1 year. Both the PGX and PSY groups demonstrated
significant reductions in energy and macronutrient in-
take as well as significant weight loss and improvements
to body composition at 52 weeks. At12 months, energy
intake and weight was significantly lower in the PGX
group compared to control but was not significantly
lower in the PSY group compared to control. Fat and
protein intake was significantly lower in the PGX group
at 3 and 6 months compared to control whereas fat and
protein intake was only significantly lower in the PSY
group at 3 months compared to control. In this regard,
the PGX group performed better than the PSY group
and was better at maintaining dietary changes and
weight loss over the 12 month intervention period.
We observed significant decreases in energy and
macronutrient intake within the two intervention groups
at 3, 6 and 12 months compared to baseline. Although
participants were instructed not to intentionally change
their diet, taking the supplements daily before each meal
resulted in a decrease in their overall food intake
(Table 1). The short term consumption of PGX has been
Table 3 Physical activity during 12 months of fibre supplementation
3 months Mean change n 6 months Mean change n 12 months Mean change n
CTR 2802.4 ± 449.3 −130.5 29 2868.2 ± 454.7 −141.2 32 3294.5 ± 525.6 415.4 30
PSY 2933 ± 443.6 620.8 30 3009.3 ± 433.2 187 35 2879.1 ± 497.8 609.6 33
PGX 2181.7 ± 470.6 751.3 27 2681.1 ± 495.5 328.2 27 2684.9 ± 619.1 194.3 22
Values are mean kJ/day ± SEM with baseline as a covariate. Mean change from baseline. Physical activity data missing at either baseline and/or at follow up time
points (n = 67). Gender ratio was unaffected at 2 males:3 females. P values were not significant. 4.184 kJ = 1 kCal
Fig. 2 Change in body weight and waist during12 months of fibre supplementation a Weight, b BMI, c Waist, d Hip, e WHR. Values are changes
in the parameters over the 12 months and are mean ± 95% CI error bars with baseline as a covariate. *indicates within group differences
compared to baseline. Different letters represent significant differences between groups p < 0.05. 3 months n = 45 CTR, 43 PSY, 40 PGX, 6 months
n = 38 CTR, 39 PSY, 32 PGX, 12 months n = 32 CTR, 36 PSY, 26 PGX. CTR Control, PSY Psyllium, PGX (PolyGlycopleX)
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previously shown to reduce hunger and food consump-
tion in healthy weight adolescents [32] and increase
satiety or feelings of fullness in normal weight adults
[36] and women who were overweight/obese [37]. This is
thought to be through its effects on appetite-regulating
peptides glucagon-like peptide-1 and peptide YY [38] and/
or due to its gel forming property that increases stomach
fullness and delays gastric emptying [36].
In previous retrospective observational clinical trials,
overweight participants lost significant weight, fat and
decreased waist circumference compared to baseline
after taking PGX for 14 weeks in addition to healthy
lifestyle changes [39]. In addition, overweight subjects
taking a PGX meal replacement and a PGX supplement
for 12 weeks also experienced significant decreases in
weight, waist and hip measurements compared to base-
line [40]. This is in agreement with the current study
and at the same daily dose of 15 g of PGX. However, in
contrast to these two previous trials, we were able to
demonstrate significant changes in weight, waist and
body fat in the PGX group compared to the control
group for 52 weeks and without prescribing any other
lifestyle changes.
Psyllium is widely used as a fibre supplement as it is
readily available and well tolerated, however findings on
the effect on metabolic syndrome risk factors have been
inconclusive [29]. De Bock et al. [41], conducted a
6 weeks intervention crossover study with 6 g/day of
psyllium supplementation in healthy adolescents and did
not observe any significant change in dietary intake,
weight or body fat percentage. In a study by Pal et al.
[20] psyllium supplementation (3.4 g psyllium per 12 g
dose of Metamucil® with 250 ml of water) caused signifi-
cant decreases in body weight, BMI and body fat
compared to the control group after 12 weeks but no
differences in waist circumference. In the current study,
the PSY group significantly decreased body weight, BMI
and body fat compared to the control group but we also
observed significant decreases in energy intake and waist
circumference. However, in contrast to the studies by de
Bock et al. [41] and Pal et al. [20], our supplement was 5 g
per dose taken with 500 ml of water. The size of the dose
Fig. 3 Change in body composition during12 months of fibre supplementation a Fat, b Fat percentage, c Android Fat, d Gynoid Fat, e Lean
Mass. Values are changes in the parameters over the 12 months and are mean ± 95% CI error bars with baseline as a covariate. *indicates within
group differences compared to baseline. Different letters represent significant differences between groups p < 0.05. 6 months n = 37 CTR, 37 PSY,
31 PGX, 12 months n = 32 CTR, 35 PSY, 26 PGX. CTR Control, PSY Psyllium, PGX (PolyGlycopleX)
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or the amount of water consumed may be an important
factor when taking a fibre supplement and an adequate
amount needs to be taken to be effective.
The weight loss and changes to body composition
observed may be due to the changes in dietary intake as
well as the possible effect of PGX on slowing gastric
emptying and absorption of nutrients in the small intes-
tine [42]. In the current study, energy intake demon-
strated significant positive relationships (p < 0.05) with
body weight (r = 0.360), abdominal fat (r = 0.223) and
lean mass (r = 0.378) across all participants. A PGX con-
taining diet has also been shown to lower food intake and
slow weight gain in rats compared to cellulose or inulin
containing chow [43]. PSY has also been shown to increase
fullness [27] but has a lower viscosity than PGX [39].
One of the strengths of this study was the duration; a
12 month intervention period. Comparable studies have
only been conducted for 14 weeks. This allowed us to
investigate the long term effects of the supplements,
especially on weight maintenance. This was a double-
blinded randomized study and supplements were packed
in identical foil sachets; however, due to the different
characteristics of the supplements, participants may have
been able to guess if they were taking a supplement or
the control. The majority of participants were female
despite a higher prevalence of overweight and obesity in
males in the Australian setting [44], so results may not
be generalizable to males or populations in other coun-
tries. Other limitations include our reliance on partici-
pant honesty and accuracy when completing food diaries
and reporting of supplement consumption. Care must
be taken when drawing conclusions from self-reported
data, however more reliable methods of measuring food
intake with low participant burden are lacking. The
intervention was not combined with any other lifestyle
modification advice, thus it would be simple for con-
sumers to incorporate into their lifestyle or there could
be added benefits if the supplements were combined
with healthy lifestyle advice.
Conclusions
The effects of PGX on appetite-regulating peptides may
also play a role in reducing dietary intake. Taking these
supplements before meals was a relatively easy task for
people to incorporate into their daily routine and would
be a simple intervention to implement. We observed
similar results between PGX and PSY supplements but
when compared to the control group, the PGX supple-
ment was superior in terms of increased weight loss and
decreased energy intake. Therefore, regular consumption
of a PolyGlycopleX® or the proprietary psyllium supple-
ment is a simple and effective method to reduce body
weight and body fat in people with overweight or obes-
ity. Further work on these two proprietary products
should be undertaken to investigate these initial findings
in other population groups and in other formats, for
example, a PGX softgel or a psyllium softgel.
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